Previous 10 | Next 10 |
--News Direct-- #BlackHistoryMonth represents an opportunity to highlight the disparities within the Black community when it comes to mental health. According to a 2018 survey, 50% of Black adults with serious mental illness did not receive treatment. We encourage foll...
Alkermes Presents New Nemvaleukin Alfa Monotherapy Data at the American Society of Clinical Oncology Genitourinary Cancers Symposium - Data From ARTISTRY-1 Clinical Trial Highlight Single-Agent, Anti-Tumor Activity of Nemvaleukin in Patients With Renal Cell Carcinoma - PR Ne...
You'd be hard-pressed to find investors who don't love it when one of their companies delivers an estimates-busting quarter. Such was the case on Wednesday with biotech Alkermes (NASDAQ: ALKS) , which crushed analysts' projections like a grape with its fourth-quarter fundamentals. I...
Image source: The Motley Fool. Alkermes (NASDAQ: ALKS) Q4 2021 Earnings Call Feb 16, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Alkermes (ALKS) Q4 2021 Earnings Call Transcript
--News Direct-- We're committed to understanding the unique needs of people living with mental illness and supporting disease awareness and education. We know there’s much to be done. Results from our recent survey conducted with Harris Poll and Depression and Bipolar Support...
Alkermes plc. (ALKS) Q4 2021 Earnings Conference Call February 16, 2022 08:00 AM ET Company Participants Sandra Coombs - SVP of IR and Corporate Affairs Richard Pops - Chairman & CEO Iain Brown - SVP & CFO Todd Nichols - SVP & CCO Conference Call Participants Brandon Folkes - Cant...
Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +55%. Upstart Holdings (NASDAQ:UPST) +32%. Eqonex (NASDAQ:EQOS) +19%. Singularity (NASDAQ:SGLY) +15%. Alkermes (NASDAQ:ALKS) +14%. Generac Holdings (NYSE:GNRC) +14%. MYT Netherlands (NYSE:MYTE) +12%. MRC Global (NYSE:MRC) +12%. NextDecade (NASDAQ:NEXT) +1...
Alkermes (ALKS +12.6%) rose following its Q4 results, which beat analysts' estimates. Q4 total revenues grew ~16% Y/Y $324.5M. Non-GAAP net income increased to $38.5M, compared to $16.5M in Q4 2020. Q4 total operating expenses were $322.1M, compared to $310.7M in Q4 2020. "The year was h...
Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +46%. Kinnate Biopharma (NASDAQ:KNTE) +9%. Corcept Therapeutics (NASDAQ:CORT) +7%. Alkermes (NASDAQ:ALKS) +5%. Celularity (NASDAQ:CELU) +3%. Losers: Masimo (NASDAQ:MASI) -36%. Baudax Bio (NASDAQ:BXRX) -20%. ...
The following slide deck was published by Alkermes plc in conjunction with their 2021 Q4 earnings call. For further details see: Alkermes plc 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...